247 related articles for article (PubMed ID: 32122329)
1. The efficacy of recombinant human soluble thrombomodulin (rhsTM) treatment for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Kamiya H; Panlaqui OM
BMC Pulm Med; 2020 Mar; 20(1):57. PubMed ID: 32122329
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study.
Abe M; Tsushima K; Matsumura T; Ishiwata T; Ichimura Y; Ikari J; Terada J; Tada Y; Sakao S; Tanabe N; Tatsumi K
Drug Des Devel Ther; 2015; 9():5755-62. PubMed ID: 26566367
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: A historically controlled study.
Sakamoto S; Shimizu H; Isshiki T; Sugino K; Kurosaki A; Homma S
Respir Investig; 2018 Mar; 56(2):136-143. PubMed ID: 29548651
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Human Thrombomodulin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
Kataoka K; Taniguchi H; Kondoh Y; Nishiyama O; Kimura T; Matsuda T; Yokoyama T; Sakamoto K; Ando M
Chest; 2015 Aug; 148(2):436-443. PubMed ID: 25811735
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
Isshiki T; Sakamoto S; Homma S
Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31137593
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
[TBL] [Abstract][Full Text] [Related]
7. Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study.
Tsushima K; Yamaguchi K; Kono Y; Yokoyama T; Kubo K; Matsumura T; Ichimura Y; Abe M; Terada J; Tatsumi K
Pulm Pharmacol Ther; 2014 Dec; 29(2):233-40. PubMed ID: 24836398
[TBL] [Abstract][Full Text] [Related]
8. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial.
Kondoh Y; Azuma A; Inoue Y; Ogura T; Sakamoto S; Tsushima K; Johkoh T; Fujimoto K; Ichikado K; Matsuzawa Y; Saito T; Kishi K; Tomii K; Sakamoto N; Aoshima M; Araya J; Izumi S; Arita M; Abe M; Yamauchi H; Shindoh J; Suda T; Okamoto M; Ebina M; Yamada Y; Tohda Y; Kawamura T; Taguchi Y; Ishii H; Hashimoto N; Abe S; Taniguchi H; Tagawa J; Bessho K; Yamamori N; Homma S
Am J Respir Crit Care Med; 2020 May; 201(9):1110-1119. PubMed ID: 31917621
[No Abstract] [Full Text] [Related]
9. Systematic review and meta-analysis of prognostic factors of acute exacerbation of idiopathic pulmonary fibrosis.
Kamiya H; Panlaqui OM
BMJ Open; 2020 Jun; 10(6):e035420. PubMed ID: 32540889
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial.
Arai T; Kida H; Ogata Y; Marumo S; Matsuoka H; Gohma I; Yamamoto S; Mori M; Sugimoto C; Tachibana K; Akira M; Inoue Y
BMJ Open Respir Res; 2020 May; 7(1):. PubMed ID: 32423894
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study.
Isshiki T; Sakamoto S; Kinoshita A; Sugino K; Kurosaki A; Homma S
Respiration; 2015; 89(3):201-7. PubMed ID: 25659984
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Wang B; Li T
Exp Ther Med; 2020 Jul; 20(1):351-358. PubMed ID: 32537001
[TBL] [Abstract][Full Text] [Related]
13. Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias.
Arai T; Kida H; Ogata Y; Marumo S; Matsuoka H; Gohma I; Yamamoto S; Mori M; Sugimoto C; Tachibana K; Akira M; Edahiro R; Hamasaki T; Inoue Y;
Respirology; 2019 Jul; 24(7):658-666. PubMed ID: 30835911
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for acute exacerbation of idiopathic pulmonary fibrosis: protocol for a systematic review and meta-analysis.
Kamiya H; Panlaqui OM
BMJ Open; 2019 May; 9(5):e028226. PubMed ID: 31129597
[TBL] [Abstract][Full Text] [Related]
15. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T
Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681
[TBL] [Abstract][Full Text] [Related]
16. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis: An exploratory randomized controlled trial.
Li JS; Zhang HL; Guo W; Wang L; Zhang D; Zhao LM; Zhou M
J Integr Med; 2023 Nov; 21(6):543-549. PubMed ID: 37993378
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of the prognosis and prognostic factors of interstitial pneumonia with autoimmune features.
Kamiya H; Panlaqui OM
BMJ Open; 2019 Dec; 9(12):e031444. PubMed ID: 31831537
[TBL] [Abstract][Full Text] [Related]
19. Bleeding events associated with recombinant human soluble thrombomodulin, classified according to renal function, in sepsis-induced disseminated intravascular coagulation.
Onoda T; Aoyama K; Suzuki M; Matsumoto T; Tanaka H; Ishii T
Int J Clin Pharmacol Ther; 2023 Jul; 61(7):297-305. PubMed ID: 37114512
[TBL] [Abstract][Full Text] [Related]
20. Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia.
Shimizu H; Sakamoto S; Isshiki T; Furuya K; Kurosaki A; Homma S
PLoS One; 2018; 13(5):e0196558. PubMed ID: 29795561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
